Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074940 · ClinicalTrials.gov registry record · Phase 2
Amivantamab in Adenoid Cystic Carcinoma
A Phase 2 study of Salivary Gland Cancer, sponsored by Trisha Wise-Draper.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT05074940: Active Phase 2 study of Salivary Gland Cancer, sponsored by Trisha Wise-Draper.
NCT05074940 is a Phase 2 study of Salivary Gland Cancer that is active but no longer recruiting, run by Trisha Wise-Draper. The registered enrollment target is 18 participants, below the 63-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074940, a Phase 2 study of Salivary Gland Cancer, is active but no longer recruiting, sponsored by Trisha Wise-Draper.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Primary Outcome
To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."
Conditions Studied
Interventions
- DRUG Amivantamab
Study Locations (5)
California
- UC San Diego Moores Cancer Center - La Jolla
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Rogel Cancer Center - University of Michigan Health - Ann Arbor
Missouri
- Washington University - School of Medicine in St. Louis - St Louis
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2028-08-05 |
| Phase | Phase 2 |
What the registry record for NCT05074940 still lists
NCT05074940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 63-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Salivary Gland Cancer appearing as the primary indexed condition, and to 1 intervention - of which Amivantamab is the first listed.
NCT05074940 lists 5 locations in 5 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT05074940 about?
NCT05074940 is a clinical study titled "Amivantamab in Adenoid Cystic Carcinoma". The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
What is the current status of trial NCT05074940?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-08-05. Estimated completion is 2028-08-05.
What conditions does trial NCT05074940 study?
This clinical trial studies the following conditions: Salivary Gland Cancer.
What interventions are being tested in trial NCT05074940?
The interventions under investigation include: Amivantamab (DRUG).
Who is sponsoring clinical trial NCT05074940?
This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05074940 being conducted?
This trial has 5 study locations across California, Massachusetts, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05074940's enrollment target sits among peer trials
18 9th of 8 the lowest of 8 other Salivary Gland Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Salivary Gland Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI